Overview

Fundamentals

Financial Fundamentals

Review latest financial statements, quality scores, TTM ratios, and peer context for this stock.

Company Verastem Inc Healthcare / Biotechnology
Latest report Q1 2026 2026-03-31
Currency USD Local financial statement archive
Filing Open filing 2026-05-07
Revenue $18.67M
Gross profit $15.62M
Operating income $-44.90M
Net income $-36.59M
Free cash flow -
Total debt -
Altman Z -8.03
Piotroski 3.00

Statements

Latest financial statement highlights

Income statement

Revenue $18.67M
Cost of revenue $3.05M
Gross profit $15.62M
Operating expenses $60.52M
EBITDA $-35.93M
Operating income $-44.90M
Income before tax $-36.59M
Net income $-36.59M
EPS -0.370

Cash flow

Operating cash flow -
Capital expenditure -
Free cash flow -
Dividends paid -
Share repurchases -
Net cash change -

Balance sheet

Cash -
Current assets -
Total assets -
Current liabilities -
Total liabilities -
Total debt -
Net debt -
Stockholders equity -

Ratios

Period and TTM ratios

Metric Period TTM
Gross margin - 83.75%
Operating margin - -344.56%
Net margin - -391.17%
Return on equity - -486.41%
Current ratio - 3.04
Quick ratio - 3.00
P/E - -1.684
Price / sales - 5.89
Debt / equity - 1.045
Interest coverage - -128.65

Peer context

Ratio comparison

Gross margin Best GOSS 99.58% VSTM 83.75% Peer average -109.10%
Return on equity Best GOSS 174.85% VSTM -486.41% Peer average -148.40%
Current ratio Best CRVS 19.81 VSTM 3.04 Peer average 9.39
Debt / equity Best KALV -104.84 VSTM 1.045 Peer average -10.22
P/E Best CRVS -22.96 VSTM -1.684 Peer average -7.00